Mark S. Chapman, Phd Email & Phone Number

Tucson, Arizona, US

Provide consulting services to companies involved in oncology drug discovery, translation, and early development. Clients include startups, biotech, and large pharma.

Build research lab capabilities and provide and execute strategic plan for start up.Crux advanced two novel programs to the drug lead stage with minimal funding.

Molecular Response offers fully-integrated solutions for the discovery and application of molecular markers that are predictive of patient response in clinical trials. Acquired by BioDuro.-Provide advice, oversight, and execution for a variety of molecular assays to further the shared goals of advancing personalized medicine in oncology.-Catalyze the.

Cambridge, MA, US

Highly productive year as contracted employee, which ended when Biogen Idec discontinued oncology drug discovery and closed the San Diego site.Evaluation of the MOA of a late clinical stage monoclonal antibody based on a new understanding of the target biology; implications for greatly expanding the cancer indications by modulating effects on the tumor.

Discovery and validation of synergistic combinations of a MEK inhibitor with other anti-cancer agents, as well as translational aspects of this kinase inhibitor during Phase 1 and Phase1/2 clinical trials, contributing to the partnering of RDEA119 to Bayer (Now BAY86-9766). Further work included early discovery and target validation. Initiating and.

Jupiter, Florida, US

Research Investigator (2006-2008)Senior Research Scientist (2003-2006)Research Scientist (2000-2003)Project Team Leader: Advanced Prostate CancerServed as team leader for a novel drug discovery effort targeting advanced prostate cancer via degradation of the androgen receptor. Project involved up to 28 FTEs, including members from all research departments..

Education record

Phd, Biochemistry, Molecular Biology

Ba, Genetics